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Dr Shaf Keshavjee (Toronto, Ontario, Canada). Dr Ailawadi,
that was a very nice presentation. I would like to congratulate your
group on demonstrating significant improvements in the outcome
of LTX in your center.The Journal of Thoracic and CAlthough you have very eloquently explained why you use the
old term ‘‘reperfusion injury’’ and the OI for comparison of your
era outcomes, I think it is very important for the audience to recog-
nize that we need to move toward standardizing nomenclature and
measurement parameters for comparison if we are going to make
meaningful observations in our patients.
I was quite pleased to see in your presentation the reference to
the PGD grading system in your current-era patients. The ISHLT
Working Group defined PGD to refer not only to RI but to acknowl-
edge the fact that much of the syndrome of PGD that you see is
related to donor factors, such as brain death, infection, aspiration,
trauma, and so on, plus ischemia, reperfusion, and the immunologic
factors in the recipient, and therefore that findings that you see
related to improvement of this syndrome after transplantation might
be attributed to many of the factors across the board. I particularly
liked your comment about program maturation because it does
speak to the attributable factor of increasing improvement in
outcomes within the multidisciplinary teams that take care of these
patients with increased volumes and increased experience. I do
think that recipient factors do play a role in what you have seen
because if you look at your data, the table does show that you
have a net increase in lower-risk patients, patients with COPD
and cystic fibrosis, and a net decrease in the higher-risk patients,
patients with pulmonary hypertension and the idiopathic pulmo-
nary fibrosis, and this certainly could contribute to outcomes,
although you might have found that in your small sample size.
Therefore my questions are as follows. Do you know when your
OPO instituted routine administration of steroids to the donors?
This might be a factor in decreasing PGD.
Dr Ailawadi. I do not have the data back in the 1990s when that
was initiated. I do know that it has been the routine in the current era.
Dr Keshavjee. That, again, was a transition that happened in the
late 1990s in most organ procurement organizations (OPO), so that
indeed could have been a factor.
Your study period spans from 1990 to 2006. You chose to split
the eras at March 2000. Why did you choose that date? Second,
your lung preservation solution, as you mentioned, went from
Euro–Collins to University of Wisconsin solution to Perfadex.
Did you look at your data separating Perfadex from the high-potas-
sium solutions, and did you find anything interesting there?
Dr Ailawadi. That is a very good question. We chose March
2000 because that is when we analyzed our previous data and our
last report had come out. That is when we first recognized that early
initiation of ECMO might be beneficial. That might be an arbitrary
date, but it is sort of when wemade that last conclusion and realized
that there might be a difference and became the transition point for
this study. We did not analyze by preservation solution. Again, the
transition point from Euro–Collins or University of Wisconsin
solution started in 1999, and by 2000, we were exclusively using
Perfadex, and that was almost superimposed with the March
2000 transition date. We can go back and look at how preservation
solution related to RI.
Dr Keshavjee. I think for the purpose of the convenience of
analyzing the database, it was probably easier, but it might be
more meaningful to go back and look at that to see what role it
played in your center.
In terms of the ECMO bridge to recovery, your mortality
decreased from 80% to 25%, although the time to institution ofardiovascular Surgery c Volume 137, Number 3 693
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improved outcome? Do you think that you are seeing a different
form or more quickly recoverable form of PGD, or are there factors
in your intensive care unit personnel that might have contributed to
this improvement?
Dr Ailawadi. I think there are multiple potential explanations
that are very difficult in this small sample size to really understand.
I think that the way we handle the ventilator is much different now
than it was in the 1990s based on the Acute Respiratory Distress
Syndrome Network data. I think there is certainly a heightened
awareness of RI or PGD in our intensive care unit, and they might
not have been as aware in the early 1990s. I do think the severity of
the injury to the lung is likely less severe now than it was in the
1990s. Even though we do not see that based on our incidence, I
think the actual amount of injury to the lung has decreased, and
we did try to show that when we analyzed the subgroup of patients
that had RI, their OI was less.
Dr Keshavjee. You demonstrated a significant increase in PGD
in the patients undergoing bilateral LTX. Do you think that this is
real, or is it just that you are more able to diagnose PGD in the
bilateral patients, whereas patients undergoing single LTX have
the advantage of having the residual native lung to provide some
function in some cases.
Dr Ailawadi. That might very well be the case. Obviously the
ISHLT criteria were created for double LTC. It is difficult to tease
that out. That is certainly a possibility.
Dr Keshavjee. Thank you very much.
Dr David M. Follette (Sacramento, Calif). I have 2 questions.
As we moved toward more aggressive use of marginal donors,
donor management strategies changed and improved. Were there
any changes in donor management strategies in your OPO that
might have contributed to having better lungs going in? You
mentioned one that we had talked about many years ago, which
was the use of steroids, but there are other factors that might
have contributed.
Dr Ailawadi. That is also a little bit difficult to tease out. Over-
all, I would say that we seem to be using a lot more marginal donors694 The Journal of Thoracic and Cardiovascular Surnow than we have in the past. Our center has matured and has had
experience with more marginal donors. I probably cannot say that
there is anything that we can pinpoint that is different aside from
OPO changes that have happened across the board at all institu-
tions.
Dr Follette. We found in San Francisco that as we got better at
taking care of marginal donors, we took even better care of the ideal
donors.
The second question is the opposite approach of the last question
our primary discussant asked. You used significantly more double
LTXs in your second cohort, and perhaps some of us felt from Dr
Patterson’s teachings many years ago that double LTXs, well taken
care of, might actually make the duration of your damage shorter.
Do you think part of your excellent result is because you had a sta-
tistically significant increase in the number of double LTXs versus
single LTXs?
Dr Ailawadi. It could be possible, although during the current
era of the study period, only 25% of our LTXs were double
LTXs, and therefore I am not sure whether I can draw that conclu-
sion. This has currently changed at our institution within the last 3
years. More than 60% of our LTXs currently are double LTXs
based on data from the ISHLT reports over the last several years,
suggesting that there is a benefit.
Dr K. Robert Shen (Rochester, Minn). Last year at this meet-
ing, you had reported on less acute rejection, less bronchiolitis
obliterans syndrome, and improved overall survival at your center
after a change in the induction regimen from an ATG-based regi-
men to daclizumab. In your data were you able to assess the effect
of the changes in the induction regimen in the 2 study periods? Do
you have any comment on that?
Dr Ailawadi. The outcomes that we studied in that report
were not 30-day mortality. They were long-term mortality, acute
rejection, and bronchiolitis obliterans syndrome. We did not link
those data with the 30-day data and PGD with this study. Further-
more, ATGAM is not given to patients with evidence of RI or
PGD. I do not think the induction agent played an important
role in RI.gery c March 2009
